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background: Despite the extensive knowledge accrued on DES in the past years, there is still lack of consistent data on the very late outcomes of 
these devices, especially after the use of 2nd generation DES.
Methods: The DESIRE registry is a prospective, single-center registry encompassing all consecutive patients treated solely with DES since May 
2002. The primary goal is the very long-term occurrence of MACE and stent thrombosis (ST). Patients were clinically followed at 1, 6 and 12 months 
and then annually. A multivariate model was built to determine independent predictors of MACE, TLR and ST.
results: A total of 5,215 patients were included. The mean age was 64 ± 11 years. DM was detected in 31% and 48% presented with acute 
coronary syndrome. SVG lesions and STEMI represented 6% and 17% of the cohort, respectively. Follow-up was obtained in 98.5% of the patients 
(median 5.6 years). Currently, 75.6% of the population is free of any MACE. TVR was performed in 8.3% of the patients. Q-wave MI rate was only 
1.7% while total ST rate was 2.4%. The majority of definite ST cases occurred between the 1st and 3rd years. Independent predictors of MACE were 
treatment of SVG (HR 1,63; 95% CI, 1.22 to 2.18, p= 0.001), multivessel disease (HR 1.39; 95% CI, 1.03 to 1.87, p<0.001), residual stenosis (HR 
1.3; 95% CI, 1.1 to 1.5, p= 0.034), DM (HR 1.6; 95% CI, 1.1 to 2.2, p= 0.006) and renal insufficiency (HR 1.5; 95% CI, 1.34 to 1.81, p= 0.004). 
Independent predictors of ST were PCI for STEMI (HR 3.5; 95% CI, 1.3 to 9.4, p= 0.013), stent length (HR 1.8; 95% CI, 1.09 to 3.02, p=0.023), 
moderate/severe calcification at lesion site (HR 2.38; 95% CI, 1.34 to 4.23, p=0.003), and in-stent residual stenosis (HR 1.04; 95% CI, 1.01 to 
1.06, p=0.003).
conclusion: The DESIRE registry probably represents the longest FU of a real world cohort treated solely with DES. In our single center experience, 
the use of DES was associated with very long-term safety and effectiveness with acceptable low rates of adverse clinical events, including ST.
